Mexico City Pledges to Fight Gentrification In Protest Aftermath
The plan's main goal will be to control rent increases, which will not be allowed to exceed inflation in Latin America's second largest economy, said Mexico City's Mayor Clara Brugada during a press conference on Wednesday. She also promised to protect local merchants with government incentives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
35 minutes ago
- Washington Post
In Trump's Washington, Palantir is winning big
Elon Musk has left government, but another Silicon Valley player is making its mark in President Donald Trump's Washington: Palantir. The software and data analytics company has garnered at least $300 million in new and expanded business since Trump took office for his second term, helping to make it the S&P's top performing stock of 2025. That includes contracts at the Federal Aviation Administration and the Centers for Disease Control and Prevention, as well as Fannie Mae, according to federal records.
Washington Post
35 minutes ago
- Washington Post
Budapest mayor questioned by police for organizing banned LGBTQ+ Pride event
BUDAPEST, Hungary — The liberal mayor of Hungary's capital was questioned by police Friday over accusations of helping organize an LGBTQ+ Pride event that the country's right-wing populist government had sought to ban. The Pride march in Budapest on June 28 was the largest event of its kind in the country's history, according to organizers, despite Prime Minister Viktor Orbán's government earlier passing an anti-LGBTQ+ law that banned such events.
Yahoo
an hour ago
- Yahoo
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ('Knight'), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, August 7, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677Webcast: or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the An archived replay will be available for 30 days at ________________________________________ About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
